Adaptimmune Therapeutics plc (ADAPY)

Adaptimmune Therapeutics plc (ADAPY) — VMCI valuation read

Across 120 indicators, Adaptimmune Therapeutics plc (ADAPY) lands at VMCI 42/100. The Healthcare sector median is 50, so the 8-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on ADAPY in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, ADAPY trades at 19.0x earnings, 6% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of 3.2x is the binding constraint on the bear case for ADAPY on the trailing balance sheet.

ADAPY fell 1.7% over the trailing 7 days, with a -6.5% read on a 30-day basis.